# GCC Dry Age Related Macular Degeneration Market > GCC Dry Age-Related Macular Degeneration (AMD) Market Research Report: Size, Share, Trend Analysis By Stage (early age-related macular degeneration, intermediate age-related macular degeneration, late age-related macular degeneration), By Age Group (above 75 years, above 60 years, above 40 years), By Diagnosis and Treatment (treatment, diagnosis), By Route of Administration (oral, injectables) and By End Userss (hospitals clinics, diagnostic centers, academic research institutes) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.52% - **2024:** $ 199.92 Million - **2025:** $ 216.51 Million - **2035:** $ 443.94 Million - **Key Players:** Novartis (CH), Regeneron Pharmaceuticals (US), Roche (CH), Bayer (DE), Allergan (IE), Apellis Pharmaceuticals (US), Santen Pharmaceutical (JP), Horizon Therapeutics (IE), Zeiss (DE) **Report ID:** MRFR/MED/43219-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/gcc-dry-age-related-macular-degeneration-market-44899 --- ## Market Summary ## **GCC Dry Age-Related Macular Degeneration (AMD) Market Overview** As per MRFR analysis, the GCC Dry Age-Related Macular Degeneration (AMD) Market Size was estimated at 110.0 (USD Million) in 2023. The GCC Dry Age-Related Macular Degeneration (AMD) Market Industry is expected to grow from 120.0(USD Million) in 2024 to 300.0 (USD Million) by 2035. The GCC Dry Age-Related Macular Degeneration (AMD) Market CAGR (growth rate) is expected to be around 8.687% during the forecast period (2025 - 2035). **Key GCC Dry Age-Related Macular Degeneration (AMD) Market Trends Highlighted** The GCC Dry Age-Related Macular Degeneration (AMD) market is witnessing significant trends driven by various factors. An aging population is one of the key market drivers, as countries in the GCC, such as Saudi Arabia and the UAE, are experiencing a rising demographic of older adults. This demographic shift increases the prevalence of AMD, consequently creating a higher demand for diagnostic tools and treatment options tailored to this condition. Furthermore, increased awareness and education about AMD, supported by health campaigns from local governments, are leading to early detection and intervention, which are crucial given the progressive nature of the disease. The GCC Dry Age-Related Macular Degeneration (AMD) market is growing along with the opportunities for advanced healthcare technologies and research in the GCC region. Local health authorities are investing in facilities and sophisticated diagnostic and therapeutic devices. Furthermore, the partnership between the healthcare and the pharmaceutical industry resulted in new therapeutic innovations and better management of GCC Dry Age-Related Macular Degeneration (AMD). Moreover, telemedicine offers specialized eye care services remotely, minimizing the travel burden for patients. Recently, there has also been a noticeable shift in government support and health policies aimed at eye care enhancement. This includes initiatives to subsidize treatments for GCC Dry Age-Related Macular Degeneration (AMD), ensuring that patients have access to necessary care. Additionally, there is a growing interest among investors in funding research and development specific to ocular conditions, further advancing the understanding and management of AMD in the region. Overall, these trends are contributing to a dynamic landscape in the GCC Dry Age-Related Macular Degeneration (AMD) market, aligning with global advancements while catering specifically to regional needs. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **GCC Dry Age-Related Macular Degeneration (AMD) Market Drivers** **Increasing Elderly Population in GCC Region** The GCC Dry Age-Related Macular Degeneration (AMD) Market industry is significantly driven by the increasing elderly population within the region. Reports indicate that by 2035, the number of individuals aged 65 and above in the GCC is expected to rise to over 5 million, accounting for nearly 12% of the total population. This demographic shift is crucial as aging is a primary risk factor for dry AMD. Organizations like the Gulf Cooperation Council Health Ministers Council have acknowledged this trend in various health policy documents, emphasizing the necessity for better senior health care services, including comprehensive eye health programs.The rising demand for AMD treatment due to the increasing elderly population presents a substantial growth opportunity for the GCC Dry Age-Related Macular Degeneration (AMD) Market, as more individuals will seek preventive and corrective measures related to age-associated vision impairments. **Advancements in Treatment Options** The ongoing technological advancements in treatment options for dry AMD are propelling the growth of the GCC Dry Age-Related Macular Degeneration (AMD) Market industry. Innovations such as the development of new pharmacological treatments and enhanced diagnostic technologies are reshaping how dry AMD is approached. According to the World Health Organization and various regional health authorities, these advanced treatments are expected to lead to a higher success rate in managing AMD symptoms among patients, thereby increasing patient enrollments in treatment programs.The establishment of medical research centers and collaborative healthcare initiatives across GCC countries, funded by national healthcare vision plans, further supports this advancement. As a result, a growing array of treatment options attracts investment and specialization within the GCC Dry Age-Related Macular Degeneration (AMD) Market. **Rising Awareness of Eye Health** Increased public awareness regarding eye health and the effects of dry AMD is having a significant impact on the GCC Dry Age-Related Macular Degeneration (AMD) Market industry. Educational campaigns conducted by health ministries and organizations such as the Qatar National Health Strategy emphasize the importance of regular eye check-ups and early detection. With statistics showing that nearly 41% of the GCC population is unaware of their susceptibility to vision disorders, health authorities are committed to raising this awareness to improve health outcomes.Greater emphasis on preventive healthcare encourages individuals, particularly the elderly, to seek medical advice and screening for AMD, leading to increased market demand as early diagnosis and treatment options become prioritized within the GCC Dry Age-Related Macular Degeneration (AMD) Market. **GCC Dry Age-Related Macular Degeneration (AMD) Market Segment Insights** **Dry Age-Related Macular Degeneration (AMD) Market Stage Insights** The GCC Dry Age-Related Macular Degeneration (AMD) Market represents a vital area of focus within the broader healthcare industry in the region, specifically relating to the Stage segment, which encompasses early, intermediate, and late age-related macular degeneration. The increasing prevalence of AMD, particularly with an aging population, has made the understanding of this segment critical for both medical practitioners and health policymakers.  Early age-related macular degeneration is often asymptomatic, yet it establishes the foundation for further progression; hence, early detection and intervention are essential in potentially preventing vision loss.Moving to intermediate age-related macular degeneration, this stage becomes more significant as patients often experience noticeable symptoms that may prompt them to seek medical advice, creating opportunities for healthcare interventions aimed at slowing the progression of the disease. Finally, late age-related macular degeneration is particularly impactful, as patients may face severe vision loss, leading to a significant decline in quality of life, thereby amplifying the urgency for effective therapeutic treatments and support systems.  The GCC region, as a melting pot of diverse cultures and lifestyles, is witnessing a growing awareness regarding AMD, influencing the healthcare sector to focus on innovative treatment modalities.In the context of market growth, each stage offers its unique challenges and potential for advancement in medical research, therapeutic developments, and healthcare policies aimed at AMD management. Moreover, with governmental initiatives aimed at improving eye health services and increasing public awareness programs about age-related eye diseases, the GCC Dry Age-Related Macular Degeneration (AMD) Market is expected to continue evolving in responsiveness to the needs of its aging population, yielding significant opportunities for stakeholders in health sectors, pharmaceuticals, and medical technology.The segmentation by Stage not only aids in tailoring appropriate interventions and public health strategies but also serves to drive ongoing research and dialogue around AMD, making it a critical focus area in the GCC healthcare landscape. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Dry Age-Related Macular Degeneration (AMD) Market Age Group Insights** The GCC Dry Age-Related Macular Degeneration (AMD) Market showcases significant insights, particularly when analyzed through the lens of age groups. As the population ages, the prevalence of AMD increases notably among individuals above 75 years, representing a critical demographic that demands focused healthcare strategies and solutions. Similarly, those above 60 years are becoming increasingly relevant as advancements in healthcare allow for higher life expectancy, subsequently amplifying the incidence of AMD. This age group often faces challenges related to early diagnosis and access to effective treatments, impacting the overall market dynamics.Furthermore, the segment above 40 years is also gaining attention as lifestyle factors begin to influence eye health, leading to an earlier onset of symptoms.  The GCC region is increasingly investing in healthcare infrastructure to address the rising AMD statistics among these age demographics, creating numerous opportunities for growth in the market. Increased awareness campaigns and proactive healthcare measures are essential in addressing the unique needs of each age group, which will significantly influence the GCC Dry Age-Related Macular Degeneration (AMD) Market dynamics in the coming years.Overall, understanding the Age Group segmentation reveals critical trends and growth drivers in this evolving field. **Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Insights** The GCC Dry Age-Related Macular Degeneration (AMD) Market is witnessing a notable transformation in its Diagnosis and Treatment segment, driven largely by the region's increasing elderly population and rising prevalence of visual impairments. With advancements in diagnostic technologies, healthcare providers are able to detect Dry AMD at earlier stages, leading to more effective treatment options and better patient outcomes. The Treatment aspect is gaining traction due to innovative therapies that focus on halting disease progression and improving vision, which is crucial in managing this chronic condition. Furthermore, the growing awareness of eye health and the importance of regular check-ups is encouraging more individuals to seek timely diagnosis, thus fueling demand. The GCC's healthcare infrastructure is continuously evolving, supported by government initiatives aimed at enhancing ophthalmic care, which augments the overall growth of the Diagnosis and Treatment market. Overall, this segment remains significant as it addresses the regional healthcare challenges posed by dry AMD, emphasizing the urgent need for comprehensive care strategies and collaborative efforts among healthcare professionals. **Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Insights** The GCC Dry Age-Related Macular Degeneration (AMD) Market is increasingly focusing on the Route of Administration, highlighting the significance of both oral and injectables. Oral administration is favored due to its non-invasive nature, thereby enhancing patient compliance and accessibility, which is essential in a region where healthcare services aim for maximum outreach. On the other hand, injectables are notable for their targeted delivery and rapid action, characteristics that are crucial in managing AMD, a prevalent condition among the aging population in the GCC region.This demographic shift towards a higher percentage of older individuals directly influences the demand for effective AMD treatment, creating a lucrative atmosphere for these administration routes.  The GCC's healthcare sector is undergoing significant transformation, fostering innovative solutions and advanced therapeutic options that prioritize patient convenience and treatment efficacy. Increasing healthcare investments and awareness of AMD are driving market growth across the region. While oral medications play a vital role in long-term management, injectables dominate due to their fast-acting and high efficacy profiles, thereby creating a balanced landscape of treatment options that address both immediate and chronic management needs in AMD. **Dry Age-Related Macular Degeneration (AMD) Market End Users Insights** The 'GCC Dry Age-Related Macular Degeneration (AMD) Market' focuses on various end users that play pivotal roles in managing this condition. Hospitals and clinics stand out as primary providers, offering essential services for diagnosis and treatment, which significantly contributes to the market’s growth. Diagnostic centers are vital as they specialize in specialized testing and early detection, greatly influencing patient outcomes and facilitating timely interventions. Meanwhile, academic and research institutes drive innovation and progress in the AMD landscape through studies and advancements in treatment methodologies, contributing to improved quality of care. Together, these segments not only cater to the growing patient population in the GCC region, where aging demographics are expected to rise but also emphasize the importance of targeted interventions and enhanced awareness regarding AMD. Overall, the collaborative synergy among these end users supports comprehensive care pathways, reinforcing their significance within the GCC Dry Age-Related Macular Degeneration (AMD) Market landscape. **GCC Dry Age-Related Macular Degeneration (AMD) Market Key Players and Competitive Insights** The GCC Dry Age-Related Macular Degeneration (AMD) Market is characterized by a competitive landscape defined by a mix of established pharmaceutical companies and emerging biotech firms. This market is gaining traction owing to a rapidly increasing aging population, increased awareness regarding eye health, and advancements in treatment modalities. As the prevalence of AMD continues to rise in the Gulf Cooperation Council region, companies in this space are focusing on product innovation, strategic partnerships, and market penetration strategies to capitalize on the growing demand for effective AMD treatments.  The competitive insights reveal a dynamic environment where companies are leveraging research and development initiatives to introduce novel therapies and improve patient outcomes while adapting to the specific needs of the GCC market.Focusing on Bayer within the GCC Dry Age-Related Macular Degeneration (AMD) Market, the company has successfully established a robust market presence with a comprehensive portfolio of ophthalmic pharmaceuticals. Bayer's strengths lie in its extensive experience in the healthcare sector, backed by significant investment in research and development tailored towards AMD treatment.  The company is known for its rigorous RD initiatives that focus on delivering innovative solutions that cater to the specific needs of patients in the region. Bayer's established relationships with healthcare providers and regulatory authorities in the GCC further bolster its market standing, allowing for quick product adoption and effective positioning in a competitive market landscape. This solid foundation enables Bayer to leverage its expertise to address the growing burden of AMD effectively.When considering Zymeworks in the context of the GCC Dry Age-Related Macular Degeneration (AMD) Market, the company has carved out a niche for itself by focusing on innovative therapies that target unmet medical needs. Zymeworks is noted for its proprietary Zymeworks' technology platform, which is designed to accelerate the development of new treatments for eye diseases, including AMD.  The company's market presence is strengthened by its strategic collaborations and partnerships that facilitate access to essential resources and enhance its research capabilities within the GCC. Zymeworks's focus on precision medicine and the customization of therapeutic options positions it favorably amidst competitors, especially with an emphasis on patient-centric solutions. Additionally, Zymeworks actively explores mergers and acquisitions to expand its portfolio and capabilities, which further solidifies its position within the rapidly evolving AMD market in the GCC region. **Key Companies in the GCC Dry Age-Related Macular Degeneration (AMD) Market Include:** - Bayer - Zymeworks - Genentech - Amgen - Roche - Karyopharm Therapeutics - EyePoint Pharmaceuticals - Alcon - Pfizer - Iveric Bio - Novartis - Santen Pharmaceutical - Hoffmann la Roche - Regeneron Pharmaceuticals - Apellis Pharmaceuticals **GCC Dry Age-Related Macular Degeneration (AMD) Market Industry Developments** In the GCC Dry Age-Related Macular Degeneration (AMD) Market, recent developments include the continued focus on innovative treatments from key players such as Bayer and Genentech, as they strive to enhance therapeutic options for patients dealing with this condition. In October 2023, Regeneron Pharmaceuticals launched a new formulation for their AMD treatment, aiming to improve patient compliance and outcomes. The market has also experienced growth in valuation driven by increasing awareness of AMD, which is reflected in recent health initiatives led by local governments across the GCC to prioritize eye health.  Additionally, mergers and acquisitions are making headlines, with Zymeworks announcing discussions for strategic partnerships to expand its AMD portfolio in December 2022. The GCC region has seen rising investments in ophthalmic research, particularly from companies like Alcon and Roche, indicative of the market's potential. The increased prevalence of AMD among the aging population in this region has been a key driver, prompting companies to accelerate their research and development efforts. Long-term studies conducted in various GCC countries since 2021 have highlighted the need for effective care strategies, showcasing the urgent demand for advancements in AMD management. **GCC Dry Age-Related Macular Degeneration (AMD) Market Segmentation Insights** ## Market Drivers ### Increasing Prevalence of AMD The GCC Dry Age Related Macular Degeneration Amd Market is experiencing growth due to the rising prevalence of age-related macular degeneration (AMD) among the aging population. As the demographic landscape shifts, with a significant portion of the population over the age of 60, the incidence of AMD is expected to rise. Reports indicate that the prevalence of AMD in the GCC region could reach approximately 10% by 2030, necessitating increased healthcare resources and treatment options. This trend underscores the urgent need for effective management strategies within the GCC Dry Age Related Macular Degeneration Amd Market, as healthcare providers and policymakers strive to address the growing burden of this condition. ### Increased Public Health Campaigns The GCC Dry Age Related Macular Degeneration Amd Market is influenced by increased public health campaigns aimed at raising awareness about AMD. Governments and non-profit organizations are actively promoting eye health and the importance of regular eye examinations, particularly among older adults. These campaigns are crucial in educating the public about risk factors and early symptoms of AMD, which can lead to earlier diagnosis and treatment. As awareness grows, the demand for eye care services is likely to rise, further driving the growth of the GCC Dry Age Related Macular Degeneration Amd Market and improving patient outcomes. ### Rising Demand for Innovative Therapies The GCC Dry Age Related Macular Degeneration Amd Market is witnessing a surge in demand for innovative therapies aimed at treating AMD. As patients and healthcare providers seek more effective treatment options, there is a growing interest in novel therapies such as anti-VEGF injections and [gene therapy](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399). The market is projected to expand as pharmaceutical companies invest in research and development to bring new products to market. This trend reflects a broader shift towards [personalized medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937), where treatments are tailored to individual patient needs, thereby enhancing the efficacy of interventions within the GCC Dry Age Related Macular Degeneration Amd Market. ### Advancements in Diagnostic Technologies The GCC Dry Age Related Macular Degeneration Amd Market is benefiting from advancements in diagnostic technologies that enhance early detection and monitoring of AMD. Innovations such as optical coherence tomography (OCT) and fundus photography are becoming more widely adopted in the region. These technologies allow for precise imaging of the retina, facilitating timely interventions that can slow disease progression. As healthcare facilities in the GCC increasingly invest in these advanced diagnostic tools, the market is likely to expand, providing patients with better access to care and improving overall outcomes in the GCC Dry Age Related Macular Degeneration Amd Market. ### Growing Investment in Healthcare Infrastructure The GCC Dry Age Related Macular Degeneration Amd Market is poised for growth due to increased investment in healthcare infrastructure across the region. Governments in GCC countries are prioritizing healthcare development, leading to the establishment of specialized eye care centers and clinics. For instance, initiatives in Saudi Arabia and the UAE aim to enhance ophthalmic services, which directly impacts the management of AMD. This investment not only improves access to treatment but also fosters research and development in AMD therapies, thereby strengthening the GCC Dry Age Related Macular Degeneration Amd Market and its capacity to address the needs of patients. ## Future Outlook The GCC Dry Age Related Macular Degeneration market is poised for growth at 7.52% CAGR from 2025 to 2035, driven by increasing aging population and advancements in treatment options. **New opportunities:** - Development of telemedicine platforms for remote consultations and monitoring. - Investment in AI-driven diagnostic tools for early detection and personalized treatment. - Expansion of specialized clinics focusing on AMD treatment and patient education. By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare needs. ## Segment Insights ### By Application: Clinical Diagnosis (Largest) vs. Research and Development (Fastest-Growing) In the GCC Dry Age Related Macular Degeneration Amd Market, the application segment is dominated by Clinical Diagnosis, which captures a significant portion of the overall market share. This reflects the critical need for accurate and timely diagnosis of age-related macular degeneration among the aging population in the GCC region. On the other hand, the Research and Development segment is rapidly expanding, driven by increasing investments in innovative therapies and diagnostic tools aimed at addressing AMD's challenges. Clinical Diagnosis (Dominant) vs. Research and Development (Emerging) Clinical Diagnosis currently holds a dominant position in the market due to its essential role in the early detection of dry AMD, which is crucial for preventing vision loss. The segment benefits from advanced diagnostic technologies and a growing awareness of the condition among healthcare providers and patients. Meanwhile, Research and Development is emerging as a vital sector within the market, fueled by the demand for novel treatments and therapies. This segment is characterized by collaboration between pharmaceutical companies, research institutions, and healthcare providers, fostering innovation and improving patient outcomes. The focus on developing more effective techniques and tools for monitoring AMD is anticipated to drive growth in this area. ### By Treatment Type: Pharmacological Therapy (Largest) vs. Surgical Intervention (Fastest-Growing) In the GCC Dry Age Related Macular Degeneration market, the distribution of market share among treatment types reveals a clear dominance of Pharmacological Therapy, which captures a significant portion of the segment. This method is widely accepted for managing dry AMD due to its effectiveness in slowing disease progression and is preferred by both patients and healthcare providers. Following closely is Surgical Intervention, which is gaining popularity as new techniques and technologies emerge, appealing to a growing number of patients seeking more immediate solutions for vision restoration. Pharmacological Therapy (Dominant) vs. Nutritional Supplements (Emerging) Pharmacological Therapy holds a dominant position in the GCC Dry Age Related Macular Degeneration market, characterized by its reliance on medications that manage symptoms and slow disease advancement. This segment is favored for its established protocols and healthcare professional endorsement, making it the first line of defense for many patients. Conversely, Nutritional Supplements are emerging as a viable alternative, particularly as awareness regarding dietary influences on AMD escalates. They appeal to health-conscious consumers looking for preventive measures and represent a growing interest in complementary treatments that enhance overall eye health. ### By Patient Demographics: Age Group (Largest) vs. Gender (Fastest-Growing) In the GCC Dry Age Related Macular Degeneration (AMD) market, the age group segment plays a pivotal role, as individuals aged 65 and above represent the largest share of diagnosed cases. This demographic is significantly affected by AMD, making them a primary focus for healthcare providers and pharmaceutical companies. Gender-wise, women are generally more affected by AMD than men, although the overall gender distribution presents a balanced view in the GCC region. Efforts are being made to understand the nuances of this demographic to tailor interventions appropriately. As the population continues to age, the market for AMD treatment is expected to expand, particularly among older adults facing age-related health issues. The prevalence of AMD is rising alongside increasing life expectancy in the GCC region. Additionally, the growing awareness and screening initiatives targeting women are contributing to the emerging recognition of gender differences in AMD. Thus, the market dynamics are shifting, with targeted approaches becoming crucial in addressing the needs of these distinct demographics. Age Group: 65+ (Dominant) vs. Gender: Women (Emerging) The dominant age group in the GCC Dry Age Related Macular Degeneration market is the 65+ demographic, characterized by a significantly higher incidence of AMD. This group is most vulnerable due to the natural aging process, and thus, they require consistent monitoring and targeted treatment options to manage their condition effectively. On the other hand, the emerging recognition of the impact of gender on AMD progression sees women gaining attention as they tend to develop the disease earlier and with more severe symptoms. As awareness rises, strategies tailored to both older adults and women will shape the future landscape of AMD treatment, ensuring that these populations receive the specialized care necessary for improved health outcomes. ### By Distribution Channel: Hospital Pharmacies (Largest) vs. Retail Pharmacies (Fastest-Growing) In the GCC Dry Age Related Macular Degeneration AMD Market, distribution channel dynamics reveal that hospital pharmacies hold the largest market share. Their robust presence in healthcare institutions facilitates access for patients with AMD, solidifying their position. Conversely, retail pharmacies are rapidly gaining traction, driven by consumer preferences for convenience and accessibility. This segment is witnessing heightened competition with various retail outlets expanding their ophthalmic product offerings to meet rising demand. Growth trends indicate that hospital pharmacies will likely maintain their dominance due to established relationships with healthcare providers. Yet, retail pharmacies are poised for significant growth, propelled by an increase in awareness of AMD and the rising incidence of eye-related disorders in the GCC region. The shifting landscape reflects changing patient behaviors as they seek more readily available treatment options. Hospital Pharmacies (Dominant) vs. Retail Pharmacies (Emerging) Hospital pharmacies serve a critical role in the GCC Dry Age Related Macular Degeneration AMD Market, providing specialized care and medication for patients requiring complex AMD treatments. Their deep integration within health systems allows for seamless coordination with ophthalmologists, ensuring patients receive tailored therapy. In contrast, retail pharmacies are emerging as a key player through increased focus on consumer health and patient education. They leverage accessible locations and extended operating hours to attract AMD patients, offering a variety of treatment options. As retail pharmacies enhance their product ranges and employ pharmacists with specialized knowledge, they are quickly becoming a vital alternative for patients seeking immediate and convenient healthcare solutions. ### By Technology: Artificial Intelligence (Largest) vs. Telemedicine (Fastest-Growing) In the GCC Dry Age Related Macular Degeneration (AMD) Market, the distribution of market share among the technology segment values shows that Artificial Intelligence leads significantly. Its capabilities in enhancing diagnostic precision and streamlining treatment pathways make it a pivotal segment. Telemedicine, while currently smaller in market share, is rapidly gaining traction due to its ability to provide remote patient monitoring and consultation services, especially in regions with limited access to specialized care. The growth trends within this segment highlight a clear trajectory towards an increased reliance on technological solutions for managing AMD. Artificial Intelligence is being widely adopted for its data analytics capabilities, driving efficiency in diagnosis and treatment recommendations. Meanwhile, telemedicine is fueled by the shift towards digital health platforms, resulting in improved patient engagement and accessibility, marking it as the fastest-growing segment in this market. Technology: Artificial Intelligence (Dominant) vs. Telemedicine (Emerging) Artificial Intelligence (AI) is the dominant force within the GCC Dry Age Related Macular Degeneration market, providing advanced solutions that enhance diagnostic accuracy and personalizing treatment plans through machine learning algorithms. As healthcare systems increasingly recognize the value of AI-driven insights, its integration into clinical practices continues to grow. In contrast, Telemedicine emerges as a vital component, revolutionizing patient interaction by offering remote consultations and monitoring. This emerging segment not only improves accessibility for patients in remote locations but also aligns with the ongoing shift towards patient-centered care. Both segments exhibit distinct characteristics that cater to the evolving landscape of healthcare technology, marking a future poised for synergistic innovation. ## Competitive Benchmarking The Dry Age Related Macular Degeneration Amd Market is currently characterized by a dynamic competitive landscape, driven by an increasing prevalence of AMD and a growing demand for innovative treatment options. Key players such as Novartis (CH), Regeneron Pharmaceuticals (US), and Roche (CH) are strategically positioned to leverage their extensive research capabilities and established market presence. Novartis (CH) focuses on advancing its portfolio through innovative therapies, while Regeneron Pharmaceuticals (US) emphasizes its strong pipeline of biologics. Roche (CH) is committed to integrating digital health solutions into its offerings, thereby enhancing patient engagement and treatment adherence. Collectively, these strategies contribute to a competitive environment that prioritizes innovation and patient-centric solutions. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Bayer (DE) and Allergan (IE) is notable, as they engage in strategic partnerships and collaborations to bolster their market positions. This collaborative approach may lead to a more cohesive competitive landscape, where shared resources and knowledge drive advancements in AMD treatment. In December 2025, Regeneron Pharmaceuticals (US) announced a collaboration with a leading telehealth provider to enhance remote patient monitoring for AMD patients. This strategic move is significant as it aligns with the growing trend of digital health integration, potentially improving patient outcomes through timely interventions and personalized care. By leveraging telehealth capabilities, Regeneron (US) may enhance its service delivery model, thereby solidifying its competitive edge in the market. In November 2025, Novartis (CH) launched a new clinical trial aimed at evaluating the efficacy of its latest AMD therapy in combination with existing treatments. This initiative underscores Novartis's commitment to innovation and its proactive approach to addressing unmet medical needs. The trial's outcomes could potentially reshape treatment protocols and reinforce Novartis's position as a leader in AMD therapeutics. In October 2025, Roche (CH) unveiled a partnership with a technology firm to develop AI-driven diagnostic tools for early detection of AMD. This collaboration highlights Roche's focus on integrating advanced technologies into its product offerings, which may enhance diagnostic accuracy and facilitate earlier interventions. The strategic importance of this move lies in its potential to transform the standard of care in AMD management, positioning Roche (CH) at the forefront of technological innovation in the field. As of January 2026, current competitive trends indicate a shift towards digitalization, sustainability, and AI integration within the Dry Age Related Macular Degeneration Amd Market. Strategic alliances are increasingly shaping the landscape, fostering innovation and enhancing operational efficiencies. The competitive differentiation appears to be evolving from traditional price-based competition to a focus on technological advancements, innovative treatment modalities, and reliable supply chains. This shift may ultimately redefine market dynamics, emphasizing the importance of adaptability and forward-thinking strategies in navigating the complexities of the AMD treatment landscape. ## Recent News & Developments In the GCC Dry Age-Related Macular Degeneration (AMD) Market, recent developments include the continued focus on innovative treatments from key players such as Bayer and Genentech, as they strive to enhance therapeutic options for patients dealing with this condition. In October 2023, Regeneron Pharmaceuticals launched a new formulation for their AMD treatment, aiming to improve patient compliance and outcomes. The market has also experienced growth in valuation driven by increasing awareness of AMD, which is reflected in recent health initiatives led by local governments across the GCC to prioritize eye health.  Additionally, mergers and acquisitions are making headlines, with Zymeworks announcing discussions for strategic partnerships to expand its AMD portfolio in December 2022. The GCC region has seen rising investments in ophthalmic research, particularly from companies like Alcon and Roche, indicative of the market's potential. The increased prevalence of AMD among the aging population in this region has been a key driver, prompting companies to accelerate their research and development efforts. Long-term studies conducted in various GCC countries since 2021 have highlighted the need for effective care strategies, showcasing the urgent demand for advancements in AMD management. ## Report Scope | MARKET SIZE 2024 | 199.92(USD Million) | | --- | --- | | MARKET SIZE 2025 | 216.51(USD Million) | | MARKET SIZE 2035 | 443.94(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.52% (2024 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Novartis (CH), Regeneron Pharmaceuticals (US), Roche (CH), Bayer (DE), Allergan (IE), Apellis Pharmaceuticals (US), Santen Pharmaceutical (JP), Horizon Therapeutics (IE), Zeiss (DE) | | Segments Covered | Application, Treatment Type, Patient Demographics, Distribution Channel, Technology | | Key Market Opportunities | Emergence of innovative therapies and diagnostic tools for GCC Dry Age Related Macular Degeneration Amd Market. | | Key Market Dynamics | Rising prevalence of Dry Age Related Macular Degeneration drives demand for innovative treatment solutions in the GCC region. | | Countries Covered | GCC | ## Frequently Asked Questions **Q: What is the projected market valuation for the GCC Dry Age Related Macular Degeneration AMD Market by 2035?** A: The projected market valuation for the GCC Dry Age Related Macular Degeneration AMD Market is expected to reach 443.94 USD Million by 2035. **Q: What was the overall market valuation for the GCC Dry Age Related Macular Degeneration AMD Market in 2024?** A: The overall market valuation for the GCC Dry Age Related Macular Degeneration AMD Market was 199.92 USD Million in 2024. **Q: What is the expected CAGR for the GCC Dry Age Related Macular Degeneration AMD Market during the forecast period 2025 - 2035?** A: The expected CAGR for the GCC Dry Age Related Macular Degeneration AMD Market during the forecast period 2025 - 2035 is 7.52%. **Q: Which companies are considered key players in the GCC Dry Age Related Macular Degeneration AMD Market?** A: Key players in the market include Novartis, Regeneron Pharmaceuticals, Roche, Bayer, Allergan, Apellis Pharmaceuticals, Santen Pharmaceutical, Horizon Therapeutics, and Zeiss. **Q: What are the main segments of the GCC Dry Age Related Macular Degeneration AMD Market by application?** A: The main segments by application include Clinical Diagnosis, Research and Development, and Patient Monitoring, with Clinical Diagnosis valued at 179.94 USD Million. **Q: How does the GCC Dry Age Related Macular Degeneration AMD Market perform in terms of treatment types?** A: In terms of treatment types, Pharmacological Therapy leads with a valuation of 179.94 USD Million, followed by Surgical Intervention and Nutritional Supplements. **Q: What demographic factors are considered in the GCC Dry Age Related Macular Degeneration AMD Market?** A: Demographic factors include Age Group, Gender, and Socioeconomic Status, with Socioeconomic Status valued at 203.94 USD Million. **Q: What distribution channels are utilized in the GCC Dry Age Related Macular Degeneration AMD Market?** A: Distribution channels include Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies, with Hospital Pharmacies valued at 179.96 USD Million. **Q: What technological advancements are influencing the GCC Dry Age Related Macular Degeneration AMD Market?** A: Technological advancements include Diagnostic Imaging, Telemedicine, and Artificial Intelligence, with Artificial Intelligence valued at 243.94 USD Million. **Q: How does the GCC Dry Age Related Macular Degeneration AMD Market's growth compare to previous years?** A: The market's growth appears robust, with a significant increase from 199.92 USD Million in 2024 to an anticipated 443.94 USD Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/gcc-dry-age-related-macular-degeneration-market-44899*